[Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].
The contribution made by adjuvant hormone therapy in the development of primary multiple endometrial adenocarcinoma (EA) in patients with breast tumors (BT) is not quite clear. The study was based on the data on 5,790 cases of BT treated at our Clinic and 4,447 females screened for hormone-dependent neoplasms. Patients with BT were found to be at high cumulative risk for endometrial carcinogenesis caused by general factors of risk and pathogenesis. The risk was particularly high in BT (stage 1) within 12 months after treatment. There was no correlation between tamoxifen treatment and significant increase in EA frequency. Promotion of tumor proliferation by tamoxifen was identified in endometrial tissue in 62 patients with BT. This may facilitate clinical manifestations of another latent EA in such patients. Dynamic surveillance of the endometrium and ovary should include ultrasonography of pelvic organs and cytologic examination (smears) of the ecto- and endocervix and endometrial aspiration biopsy.